Drug-Development Challenges for Small Biopharmaceutical Companies
نویسندگان
چکیده
منابع مشابه
DRUG DEVELOPMENT Immunogenicity: anticipating and avoiding issues for biopharmaceutical development
an immune response in the recipient: this may be the intended effect, as in the case of vaccines, or unintended. Depending on the nature and magnitude of the response, unintended immunogenicity can impact negatively on overall clinical benefit and risk. All biopharmaceutical products have an intrinsic immunogenic potential by virtue of molecular features that can stimulate cells of the adaptive...
متن کاملNew Challenges for Biopharmaceutical Process Development.PDF
The U.S. Food and Drug Administration (FDA), through the Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), has long identified that the development of biopharmaceutical products is becoming increasingly challenging, and is inefficient and costly. The agency has also commented that superior product-development sciences are needed to address the c...
متن کاملStandardization and Certification Challenges for Biopharmaceutical Plants
C O M P U T E R 0 0 1 8 9 1 6 2 / 1 7 / $ 3 3 . 0 0 © 2 0 1 7 I E E E P U B L I S H E D B Y T H E I E E E C O M P U T E R S O C I E T Y S E P T E M B E R 2 0 1 7 83 Bioprocessing—a technique that produces biological material, such as genetically engineered microbial strains and commercially useful chemicals—is big business in the US and growing quickly around the world. An increasing number of ...
متن کاملModelling of the biopharmaceutical drug development pathway and portfolio management
Given the time, cost and risk associated with drug development, biopharmaceutical companies typically need to have a portfolio of drugs in development to be successful. Current pressures of cost and speed to market are driving the need for more effective means of assessing the value and risks of such drug portfolios. This paper presents research to generate a prototype computer tool developed t...
متن کاملDrug Therapy for Small Abdominal Aortic Aneurysm
Dear Editor,Abdominal aortic aneurysm is often asymptomatic, less recognized, and causes considerable mortality and morbidity, if missed. The incidence varies from country to country and the occurrence is influenced by modifiable (smoking, coronary heart disease, hypertension, dyslipidemia, and prolonged steroid therapy) and non-modifiable risk factors (increasing age, male gender, and positive...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2017
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmra1510070